Please login to the form below

Not currently logged in


This page shows the latest risdiplam news and features for those working in and with pharma, biotech and healthcare.

Roche scores FDA priority review for risdiplam in SMA

Roche scores FDA priority review for risdiplam in SMA

Roche’s risdiplam is a closer competitor to Biogen’s drug, based on its target age range. ... It could however have a dosing advantage – risdiplam is an orally-active treatment, while Spinraza is injected into the spine.

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word